Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

Junshi Biosciences and Coherus to meet with US FDA to discuss 1L NSCLC BLA supplement submission SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive results of an interim analysis of overall survival from the […]

Read More

Annual Changes to the Nasdaq Biotechnology Index

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20, 2021. The Index is designed to track the performance of a set of securities listed on The […]

Read More

Annual Changes to the Nasdaq-100 Index®

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (Nasdaq: NDX), which will become effective prior to market open on Monday, December 20, 2021. The following six companies will be added to the Index: Airbnb, Inc. (Nasdaq: ABNB), Fortinet, Inc. (Nasdaq: […]

Read More

Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC

6th indication for toripalimab submitted in China SHANGHAI, China, Dec. 10, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has accepted the company’s supplemental New Drug Application (“sNDA”) […]

Read More

Spend Matters Secures Investment From Copley Equity Partners

Proceeds to Fund Continued Growth in Procurement While Expanding into Adjacent Markets BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) — Copley Equity Partners, LLC (“Copley”), a private investment firm focused on lower middle-market companies with strong growth opportunities, today announced that it has made an investment in Spend Matters, a proprietary tech-enabled data platform that drives […]

Read More